Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/RC3H1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RC3H1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RC3H1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/RC3H1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RC3H1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RC3H1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/RC3H1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RC3H1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RC3H1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000640211 | Liver | Cirrhotic | mRNA catabolic process | 109/4634 | 232/18723 | 1.30e-13 | 1.09e-11 | 109 |
GO:000095611 | Liver | Cirrhotic | nuclear-transcribed mRNA catabolic process | 58/4634 | 112/18723 | 6.55e-10 | 3.06e-08 | 58 |
GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
GO:190331311 | Liver | Cirrhotic | positive regulation of mRNA metabolic process | 56/4634 | 118/18723 | 7.05e-08 | 2.14e-06 | 56 |
GO:004348811 | Liver | Cirrhotic | regulation of mRNA stability | 69/4634 | 158/18723 | 1.44e-07 | 3.87e-06 | 69 |
GO:004348711 | Liver | Cirrhotic | regulation of RNA stability | 73/4634 | 170/18723 | 1.44e-07 | 3.87e-06 | 73 |
GO:006101311 | Liver | Cirrhotic | regulation of mRNA catabolic process | 70/4634 | 166/18723 | 5.91e-07 | 1.30e-05 | 70 |
GO:000020911 | Liver | Cirrhotic | protein polyubiquitination | 89/4634 | 236/18723 | 6.09e-06 | 9.80e-05 | 89 |
GO:003424911 | Liver | Cirrhotic | negative regulation of cellular amide metabolic process | 100/4634 | 273/18723 | 7.34e-06 | 1.13e-04 | 100 |
GO:19012241 | Liver | Cirrhotic | positive regulation of NIK/NF-kappaB signaling | 33/4634 | 69/18723 | 2.70e-05 | 3.46e-04 | 33 |
GO:006115711 | Liver | Cirrhotic | mRNA destabilization | 38/4634 | 84/18723 | 3.34e-05 | 4.13e-04 | 38 |
GO:005077911 | Liver | Cirrhotic | RNA destabilization | 39/4634 | 88/18723 | 4.69e-05 | 5.47e-04 | 39 |
GO:006101411 | Liver | Cirrhotic | positive regulation of mRNA catabolic process | 38/4634 | 87/18723 | 8.55e-05 | 9.25e-04 | 38 |
GO:001714811 | Liver | Cirrhotic | negative regulation of translation | 87/4634 | 245/18723 | 1.01e-04 | 1.05e-03 | 87 |
GO:1901222 | Liver | Cirrhotic | regulation of NIK/NF-kappaB signaling | 46/4634 | 112/18723 | 1.03e-04 | 1.06e-03 | 46 |
GO:000028811 | Liver | Cirrhotic | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 26/4634 | 56/18723 | 3.40e-04 | 2.91e-03 | 26 |
GO:0038061 | Liver | Cirrhotic | NIK/NF-kappaB signaling | 54/4634 | 143/18723 | 3.64e-04 | 3.07e-03 | 54 |
GO:190015111 | Liver | Cirrhotic | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:00705553 | Liver | Cirrhotic | response to interleukin-1 | 52/4634 | 143/18723 | 1.27e-03 | 8.54e-03 | 52 |
GO:00339624 | Liver | Cirrhotic | P-body assembly | 12/4634 | 21/18723 | 1.53e-03 | 9.98e-03 | 12 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RC3H1 | SNV | Missense_Mutation | | c.2156N>G | p.Tyr719Cys | p.Y719C | Q5TC82 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-A8-A06T-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
RC3H1 | SNV | Missense_Mutation | | c.1324N>A | p.Glu442Lys | p.E442K | Q5TC82 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A8-A08B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
RC3H1 | SNV | Missense_Mutation | | c.2083G>A | p.Glu695Lys | p.E695K | Q5TC82 | protein_coding | deleterious(0.01) | benign(0.021) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RC3H1 | SNV | Missense_Mutation | | c.392G>A | p.Arg131His | p.R131H | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RC3H1 | SNV | Missense_Mutation | novel | c.1426N>G | p.Ile476Val | p.I476V | Q5TC82 | protein_coding | tolerated(1) | benign(0.028) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
RC3H1 | SNV | Missense_Mutation | | c.937N>G | p.His313Asp | p.H313D | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
RC3H1 | SNV | Missense_Mutation | | c.26N>A | p.Thr9Lys | p.T9K | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
RC3H1 | SNV | Missense_Mutation | | c.2668T>C | p.Tyr890His | p.Y890H | Q5TC82 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RC3H1 | SNV | Missense_Mutation | | c.1825N>G | p.Gln609Glu | p.Q609E | Q5TC82 | protein_coding | tolerated(0.56) | benign(0.005) | TCGA-E2-A1LA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
RC3H1 | SNV | Missense_Mutation | | c.835C>G | p.Leu279Val | p.L279V | Q5TC82 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |